Fundraising Fox
Exogenus T
Founded 2015 · 13 employees on LinkedIn · 1 known investors
Find your way into Exogenus T
Sign up to see every warm intro you have to Exogenus T
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Exogenus T team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Exogenus develops therapeutic exosomes derived from umbilical cord blood cells to treat autoimmune diseases through immune system rebalancing. The company targets multiple autoimmune disease indications where existing pharmaceutical treatments carry significant side effects.
Founders & leadership
JS
Joana Simões CorreiaCEOJoana Simões Correia holds a PhD in Human Biology and has spent over 15 years in research on human diseases including cancer genetics and regenerative medicine. She co-founded and leads Exogenus Therapeutics, where she has directed the company's research and development activities since 2015 focusing on therapeutic exosomes derived from umbilical cord blood.
Investors · 1
Frequently asked questions
- What does Exogenus T do?
- Exogenus develops therapeutic exosomes derived from umbilical cord blood cells to treat autoimmune diseases through immune system rebalancing. The company targets multiple autoimmune disease indications where existing pharmaceutical treatments carry significant side effects.
- Who are Exogenus T's investors?
- Exogenus T's investors include 3xP Global.